Compare RDY & SOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | SOLS |
|---|---|---|
| Founded | 1984 | 2025 |
| Country | India | United States |
| Employees | N/A | 4400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.5B |
| IPO Year | 2001 | N/A |
| Metric | RDY | SOLS |
|---|---|---|
| Price | $13.84 | $69.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $16.90 | ★ $72.75 |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 05-08-2026 | 05-03-2026 |
| Dividend Yield | ★ 0.51% | 0.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.50 | $6.46 |
| Revenue Next Year | $2.96 | $5.00 |
| P/E Ratio | ★ $18.67 | $54.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $40.43 |
| 52 Week High | $16.17 | $84.44 |
| Indicator | RDY | SOLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 39.68 |
| Support Level | $12.97 | $47.09 |
| Resistance Level | $14.14 | $83.07 |
| Average True Range (ATR) | 0.24 | 3.36 |
| MACD | -0.08 | -1.15 |
| Stochastic Oscillator | 3.55 | 0.09 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.